Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. MedRx Co., Ltd
  6. News
  7. Summary
    4586   JP3921220004

MEDRX CO., LTD

(4586)
  Report
Delayed Japan Exchange  -  01:00:00 2023-02-07 am EST
173.00 JPY   +7.45%
2022Medrx : Fair Research Inc. Report (September 14, 2022)
PU
2022Medrx : H1 FY2022 Business Highlight & Financial Results
PU
2022MedRx Co., Ltd announced that it expects to receive ¥3.904 million in funding
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Evolution Capital Management Submits Shareholder Proposal to MedRx

12/23/2019 | 11:00pm EST
share with twitter
share with LinkedIn
share with facebook

On December 24, 2019, Evolution Capital Management, LLC announced that it has submitted a notification with the purpose of provide advice and important suggestion acts to management according to circumstances.


© S&P Capital IQ 2019
All news about MEDRX CO., LTD
2022Medrx : Fair Research Inc. Report (September 14, 2022)
PU
2022Medrx : H1 FY2022 Business Highlight & Financial Results
PU
2022MedRx Co., Ltd announced that it expects to receive ¥3.904 million in funding
CI
2021MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquari..
CI
2021MedRx Co., Ltd announced that it expects to receive funding from Macquarie Bank Limited..
CI
2020Evolution Capital Withdraws Shareholder Proposal to MedRx
CI
2020MedRx Co., Ltd announced that it has received ¥206.406 million in funding from Japan In..
CI
2020MedRx Co., Ltd announced that it expects to receive ¥206.406 million in funding from Ja..
CI
2020MedRx Co., Ltd Announces Consolidated Financial Results for the Fiscal Year Ended Decem..
CI
2019Evolution Capital Management Submits Shareholder Proposal to MedRx
CI
More news
Financials
Sales 2022 329 M 2,50 M 2,50 M
Net income 2022 -1 004 M -7,64 M -7,64 M
Net cash 2022 656 M 4,99 M 4,99 M
P/E ratio 2022 -4,24x
Yield 2022 -
Capitalization 4 883 M 37,2 M 37,2 M
EV / Sales 2022 12,8x
EV / Sales 2023 28,4x
Nbr of Employees 23
Free-Float 83,2%
Chart MEDRX CO., LTD
Duration : Period :
MedRx Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDRX CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 173,00 JPY
Average target price 130,00 JPY
Spread / Average Target -24,9%
EPS Revisions
Managers and Directors
Yonehiro Matsumura President & Representative Director
Masayoshi Matsumura Chairman
Hidetoshi Hamamoto Director & Research Manager
Ken Fujioka Director & Manager-Corporate Administration
Kunio Iwatani Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
MEDRX CO., LTD69.47%34
MERCK KGAA1.88%86 031
KYOWA KIRIN CO. LTD.-4.64%11 665
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD-0.45%5 644
SK BIOPHARMACEUTICALS CO., LTD.0.14%4 434
BETTA PHARMACEUTICALS CO., LTD.27.56%3 885